Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
Verrica Pharmaceuticals Inc. (VRCA)
Last verrica pharmaceuticals inc. earnings: 3/13 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. to its Board of Directors. “We are pleased to welcome Dr. Gavin Corcoran to our Board of Directors,” said Jayson Rieger, Ph.D., MBA, President and Chief Executive Officer of Verrica Pharmaceuticals. “Gavin is a highly accomplished pharmaceutical executive with an outstanding track record of successfully developing and launching innovative medicines, as well as creating significant value through strategic transactions. As Verrica continues to grow its commercial business and advance its late-stage pipeline, Gavin’s insights and experience will be extremely helpful as we seek to achieve our strategic objectives.” “Verrica is now reaching an important inflection point in its commercial busine
Show less
Read more
Impact Snapshot
Event Time:
VRCA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRCA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRCA alerts
High impacting Verrica Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VRCA
News
- Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock.MarketBeat
- Verrica Pharmaceuticals (NASDAQ:VRCA) was given a new $17.00 price target on by analysts at Loop Capital.MarketBeat
- Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash RunwayGlobeNewswire
- Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Verrica Pharmaceuticals Non-GAAP EPS of $0.13, revenue of $14.3M [Seeking Alpha]Seeking Alpha
VRCA
Earnings
- 11/14/25 - Beat
VRCA
Sec Filings
- 12/15/25 - Form S-3
- 12/10/25 - Form D
- 12/3/25 - Form SCHEDULE
- VRCA's page on the SEC website